PHOENIX, AZ / ACCESSWIRE / March 20, 2019 / Uptick Newswire Stock Day Podcast welcomed Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“the Company”), a neurotech company focused on neurological wellness. President and CEO, Phil Deschamps, joined Stock Day host Everett Jolly.
Jolly began the interview by asking Deschamps to share some background information about the Company. Deschamps explained that the Company was founded in June of 2014 and has been developing the PoNS Device and PoNS Treatment program. Essentially, this technology improves the brain’s ability to heal itself, which is useful in treating a variety of symptoms related to brain trauma.
Jolly then noted that the PoNS technology has been used in Canada and asked how the response has been in that area. Deschamps shared that there has been interest in Canada to use the technology to treat balance deficit disorders. In Canada, there are 350,000 individuals that suffer from this symptom, so the need for this technology is substantial.
Jolly then asked about the Company’s next steps. Deschamps explained that the Company has already started treating patients with the PoNS device and the results have proven to be effective. In fact, the first patients who received treatment reached out to Deschamps personally to thank him for developing a product that provides hope to individuals with their conditions.
Deschamps also explained that the Company has recently announced that they have responded to the FDA Additional Information letter and believe they have answered all FDA questions substantially. For now, the Company is simply awaiting the final decision and processing. “It could be anytime now, and we look forward to when it happens.”, added Deschamps.
Deschamps also shared that the need for this technology is substantial, as brain related injuries and their symptoms are typically incredibly difficult to treat. The Company is hoping to aid in the healing and symptoms of illnesses like multiple sclerosis, strokes, and cerebral palsy using the PoNS device and treatment program once the clinical trials and proper regulatory submissions are done.
“We hope over time to make a huge dent in this intractable spot for medicine.”, stated Deschamps.
Jolly then inquired about the Company’s current stock value and noted that it seems very low. Deschamps explained that there is massive opportunity for the value of the stock to rise, especially given the pending FDA approval. Looking at the bigger picture, Deschamps also shared his belief in the impact the PoNS technology can have for patients around the world.
To hear Phil Deschamps’ entire interview, follow the link to the podcast here: https://upticknewswire.com/featured-interview-ceo-phillipe-deschamps-of-helius-medical-technologies-inc-nasdaq-hsdt-2/
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first product in development is the Portable Neuromodulation Stimulator (PoNS). For more information, visit www.heliusmedical.com.
About the PoNS Device and PoNS Treatment
The Portable Neuromodulation Stimulator (PoNS) is an investigational, non-invasive, medical device in the United States, for which Helius has requested De Novo classification and 510(k) clearance from the Food and Drug Administration for the treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury when combined with targeted physical therapy. PoNS is a licensed class II medical device in Canada. PoNS is currently not commercially available in the United States or the European Union.
Investor Relations Contact:
Westwicke Partners on behalf of Helius Medical Technologies, Inc.
Mike Piccinino, CFA
About Uptick Newswire and the “Stock Day” Podcast
Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.
SOURCE: Uptick Newswire